- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00675649
A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Parallel-group Study Evaluating the Efficacy and Safety of Golimumab Administered Subcutaneously in Symptomatic Subjects With Severe, Persistent Asthma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Golimumab is a type of tumor necrosis factor (TNF) inhibitor. TNF is a naturally occurring substance in the body and this substance may cause long-term inflammation. Golimumab may help treat this disease by blocking the activity of TNF in the body and reducing the symptoms of severe, persistent asthma.This study will assess the safety and effectiveness of subcutaneously (under the skin) administered golimumab and determine if there is a reduction of signs and symptoms in patients with active severe, persistent asthma. The effect of subcutaneously (SC) administered golimumab on the quality of life in patients with severe, persistent asthma will also be assessed. About 200 patients will take part in the study at approximately 60 centers worldwide. Participation in the study will last for about 42 weeks. The study consists of 3 phases: the screening phase (lasting between 1 and 4 weeks), the treatment phase (20 weeks), and the follow-up phase (20 weeks). Visits are scheduled to occur once every 4 weeks during the treatment and follow-up phases of the study. Patients eligible to take part in this study will be randomly placed into one of the following study groups: Group 1: Placebo (an inactive or dummy treatment that looks the same as the study drug, golimumab, but does not contain any active medication) from Week 0 through Week 20. Group 2: Golimumab 100 mg from Week 0 through Week 20. This study is "blinded." This means that neither patient nor study doctor will know in which group a patient is placed. However, if needed for safety or health reasons, the study doctor can find out a patient's study group at any time.
Patients will receive an injection (under the skin) of placebo (Group 1) or golimumab 100 mg (Group 2) every 4 weeks from Week 0 through Week 20.
Studietyp
Fas
- Fas 2
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Physician diagnosis of asthma for >= 3 years and a diagnosis of severe, persistent asthma for >= 1 year prior to screening
- Reversible airway obstruction
- Continuous treatment with high dose inhaled corticosteroids and long-acting Beta2-agonist for at least 3 months prior to screening
- At least 1 occasion in the previous 6 months when worsening of asthma required treatment with additional steroids (intravenous or oral)
- Score of >= 2 points on the Asthma Control Questionnaire (ACQ) at screening
Exclusion Criteria:
- Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder
- Life-threatening asthma attack requiring intubation in the 6-month period prior to screening
- Steroid use at a dose > 20 mg of prednisone at the screening visit
- Known malignancy or history of malignancy
- Previous exposure to anti-TNF therapies
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 001
|
100 mg sc injection every 4 weeks from week 0 to week 20
|
Placebo-jämförare: 002
|
placebo sc injection every 4 weeks from week 0 to week 20
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
The primary endpoint is the time to first severe asthma exacerbation through Week 24.
Tidsram: Week 24
|
Week 24
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Secondary endpoints include the number of severe asthma exacerbations through Week 24, number of clinically significant asthma exacerbations through Week 24, and change from baseline in Asthma Quality of Life Questionnaire (AQLQ) overall score at Week 24
Tidsram: Week 24
|
Week 24
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Immunsystemets sjukdomar
- Lungsjukdomar
- Överkänslighet, Omedelbar
- Bronkialsjukdomar
- Lungsjukdomar, obstruktiv
- Respiratorisk överkänslighet
- Överkänslighet
- Astma
- Läkemedels fysiologiska effekter
- Antiinflammatoriska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Tumörnekrosfaktorinhibitorer
- Golimumab
Andra studie-ID-nummer
- CR014980
- C0524T26
- EudraCT No.: 2007-005699-15
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på CNTO 148 / Golimumab
-
Centocor, Inc.Schering-PloughAvslutadSpondylit, ankyloserandeFörenta staterna, Tyskland, Finland, Taiwan, Korea, Republiken av, Kanada, Belgien, Nederländerna, Frankrike
-
Janssen Pharmaceutical K.K.Mitsubishi Tanabe Pharma CorporationAvslutad
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCAvslutadKolit, ulcerösFörenta staterna, Polen, Tyskland, Frankrike, Indien, Rumänien, Serbien, Ukraina, Israel, Kanada, Nederländerna, Sverige, Nya Zeeland, Ryska Federationen, Australien, Belgien, Ungern, Bulgarien, Slovakien, Lettland, Litauen, Österrike
-
Janssen Research & Development, LLCSchering-PloughAvslutadJuvenil idiopatisk artritPolen, Förenta staterna, Tyskland, Belgien, Kanada, Finland, Nederländerna, Ryska Federationen, Brasilien, Österrike, Litauen, Mexiko
-
University of WashingtonJanssen Scientific Affairs, LLCRekryteringKastrationsresistent prostatakarcinom | Prostata AdenocarcinomFörenta staterna
-
Janssen Pharmaceutical K.K.Mitsubishi Tanabe Pharma CorporationAvslutad
-
Centocor, Inc.AvslutadDiabetes mellitus, typ 2Förenta staterna
-
Janssen-Cilag International NVAvslutad
-
Janssen Inc.AvslutadPsoriasisFörenta staterna, Polen, Kanada, Belgien, Tyskland
-
Centocor, Inc.AvslutadRetinit PigmentosaFörenta staterna